Life Science Compliance Update

October 02, 2014

Physician Payments Sunshine: Columbia Seeks to Join Global Transparency Trend


The Colombia Ministry of Health and Social Protection recently published a draft law which would require pharmaceutical and device manufacturers to disclose their payments and in-kind transfers to “those who participate in any manner in the provision, insurance, or education in the health sector.” The reports will be made public on a searchable database.

Columbia follows a long list of countries that have reporting laws, including the U.S. Sunshine Act, EFPIA in the European Union, and the French Sunshine Act.

View Columbia's draft resolution (translated to English) here

“[M]any pharmaceutical companies operating in Colombia already disclose information in their home countries and other countries in which they conduct their operations,” Columbia notes in their resolution (emphasis added).  The draft does not specify whether the reporting obligations would be restricted to companies “operating in Colombia,” nor does it describe what is meant by “operating.” 

If the draft resolution is finalized, the Ministry provides that "voluntary registration" and reporting of payments would start January 1, 2015. This initial disclosure would only relate to “general information about the payments.” Registration and reporting of payments would be mandatory starting January 1, 2016, and would require “information identifying the recipients.”  

The draft resolution states that the "invitation to register" applies to manufacturers, distributors, importers, traders, or participants in the supply chain of drugs, supplies, devices, and medical equipment or any other health technology. 

These parties must report on payments made to health practitioners that perscribe health services. Furthermore, the draft law requires reporting on payments made to virtually anyone remotely involved in healthcare: administrative staff that work in the health sector, professional organizations, associations, clinics, hospitals, universities, students in healthcare fields, patient organizations, and patients, among others. 

Manufacturers and distributors must submit direct payments and transfers of value of any type, including those made in cash and in kind. The draft includes a non-exhaustive list, which includes:

  • funding attendance at medical, academic, or scientific events
  • funding for meals and other recreational events
  • payments for patient monitoring
  • funding for research
  • medical continuing education activities
  • medical equipment

Thus, Columbia's law explicitly states that many transfers of value that are excluded under the U.S. Sunshine Act are to be reported on in Columbia. The only four exceptions are as follows (interestingly many dollar thresholds are in proportion to the minimum wage, which works out to a monthly wage of COL$589,500 (US$333)):

  1. Payments by parties obligated to register made to someone with a employment or contractual relationship to develop the social objective of the activity of the payer shall not be registered.
  2. Medical samples or diagnostic tests shall not be registered "unless their individual market value exceeds four minimum wages (SMLMV)."
  3. Printed promotional information shall not be registered unless it is part of a continuing education or recreational activity.
  4. Transfers of value of less than half (1/2) a monthly legal minimum wage need not be registered, unless they exceed one monthly legal minimum wage in one year. 

Reporting entities must then consolidate their payments into categories (such as food and drink, research, gifts). These are almost identical to the US Sunshine Act categories. The reports must also include the "form" of payment--cash, in kind items, stocks. 

As noted above, the current draft contemplate different stages for implementation. The first stage will last one year and include two registrations--first, payments made during the first half of 2015 will be completed before October 31, 2015. The second registration will cover payments made in the second half of 2015 and will be completed before April 30, 2016. 

The second phase will be mandatory, and requires individual, non-aggregated payment reports. It is slated to begin January 2016 and its rules will remain in place going forward, with reports required before April 30 each year. Notably, "[t]he only payments that will not be individually identified are those given to patients and the registry will maintain the aggregate amount," the draft states. "Those that are transferred to patient associations shall be reported individually."


We will continue to follow updates on Columbia's disclosure law, as well as other Sunshine initiatives. View our coverage of the Open Payments release here

In the meantime, Columbia provides a fairly succinct answer to most disclosure inquiries we could think of: "In case of a question as to whether a payment or transfer of value should or should not be registered, it shall be registered."  

July 29, 2014

Medicines Australia Code of Conduct: Payment Reporting Starts October 1, 2015


Transparency is increasingly a global phenomenon. Australia is no exception. Medicines Australia, Australia's industry body, recently revamped the disclosure provisions of its Code of Conduct, and sent the reforms to the Australian Competition and Consumer Commission (ACCC) for approval. The new Code will require Medicines Australia's member companies to report on an individual basis a wide range of payments and transfers of value to healthcare professionals, as well as sponsorships of third party educational meetings and symposia. The Australian requirements are similar to the United States' Physician Payments Sunshine Act, but there are notable differences in the policies.

The new version of the Code—Edition 18—was unanimously adopted by Medicines Australia's members at a general meeting on June 17, 2014. The ACCC authorization process is expected to take around six months and, if authorized, the new Code will come into effect in January 2015, with the new transparency reporting starting October 1, 2015. The new Edition preserves the reporting requirements of Edition 17 of the Code until September 30, 2014, which require aggregate rather than individualized reporting at the healthcare professional level.

Under the new Code, the following activities would be reported by pharmaceutical companies for individual healthcare professionals, by name, with the amount of the payment or transfer of value:

  • Consulting fees and/or speaking fees at educational event.
  • Sponsorship of a healthcare professional to attend an educational event: airfares, accommodation and/or registration fees (whether held within or outside Australia).
  • Fees paid to healthcare professional consultants in Australia, or to their employers on their behalf, for specific services rendered by them: consulting fees, accommodation and airfares (whether within or outside Australia).
  • Fees paid to healthcare professionals in their role as Advisory Board members: sitting fees, accommodation and airfares (whether within or outside Australia).
  • Fees paid to healthcare professionals for the purpose of market research ONLY where the identity of the healthcare professional is known to the company.
  • Payment of an educational grant or sponsorship to a specific healthcare professional

The following would NOT be required to be reported:

  • Payments to consultants in relation to research and development work, including the conduct of clinical trials.
  • Hospitality (food and beverages): The cost of any meal (including drinks) provided by a company must be below the defined limit set in the Code ($120 for food and beverages)
  • Airport ground transfers, taxis, parking fees
  • Venue costs (e.g. room and/or audio-visual equipment hire)


As you can see, while the Code requires broader reporting than the United States for speaking events, the Australian Code exempts clinical trials from reporting as well as providing for a much larger food limit ($120 compared to $10). After the recent revision to the Sunshine Act, the CME speaking events policy may not even give us the edge there.

We also noticed that Australia's definition of "Transfer of Value" includes both direct and indirect transfers, like the United States. However, the Australian Code defines indirect transfer of value as "one made by a third party on behalf of a company for the benefit of a recipient where the identity of the company is known to, or can be identified by, the recipient." (p. 94 of the revised code). This is an interesting standard, considering the onus is on the manufacturers to report the transfer of value. In the US, if a payment meets the definition of an indirect payment in § 403.902, then the payment can be excluded from the reporting requirements if the applicable manufacturer does not ''know'' the identity of the covered recipient.

Another interesting aspect of the Australian Code is the concept of informed consent from physicians. "Each company must establish a means to ensure informed consent and maintenance of records which comply with Australian Privacy legislation," the Code states. "Where recipients of transfers of value cannot be identified for legal reasons, the amount attributable to such transfers must be reported on an aggregate basis by each company. The number of recipients involved must be stated and the aggregate amount attributable to transfers of value to such recipients."

Medicines Australia will make publicly available on its website the completed reports provided by each Member Company within two months of the date on which the reports must be submitted to Medicines Australia. The first report is scheduled to be published on August 31, 2016. Like in the United States, companies must provide Australian healthcare professionals for whom they have collected information about payments the opportunity to review and submit corrections to the information during a 6-week period before the public disclosure.

Now that the US system is in its Dispute Resolution phase, perhaps the most striking difference between Codes is that in Australia, "[i]f a healthcare professional does not agree to the information being disclosed with their name, the expenditure will be reported in aggregate with the number of healthcare professionals it relates to." This is a completely different approach than the US Sunshine Act, which allows manufacturers to unilaterally dismiss complaints by healthcare professionals.


The Code of Conduct, June 2014:

Medicines Australia's press release, July 2, 2014

Thanks to Health Market Science for the information leading to this article on Australia's new code.

July 14, 2014

Physician Payment Sunshine Act: FDA Issues Revised Draft Guidance for Reporting Drug Samples

The Affordable Care Act puts a lot of emphasis on transparency. Section 6002, the Physician Payments Sunshine Act, requires manufacturers to report to the Centers for Medicare and Medicaid Services (CMS) almost every transfer of value they make to doctors—from lunches to peer-reviewed medical journals. Another part of the Act, Section 6004, requires manufacturers and distributors to submit to the Food and Drug Administration (FDA) reams of data about drug samples.

The distribution of drug samples is already highly regulated. The Prescription Drug Marketing Act (PDMA), which has been in place since 1987, requires that drug manufacturers and distributors maintain records of the samples they distribute. Companies are only allowed to distribute samples in response to a formal written request containing information about both the manufacturer and the practitioner making the request. Only practitioners licensed in their state to prescribe the requested drugs may even request samples in the first place. Manufacturers then have to maintain thorough records of their drug samples, and conduct annual inventories of their products.

Now, in addition to maintaining records, Section 6004 of ACA requires manufacturers and distributors to submit much of the same information to FDA, including:

  • The identity and quantity of drug samples requested
  • The identity and quantity of drug samples distributed
  • The name, address, professional designation, and signature of any person who makes or signs for the request
  • Any other category of information determined appropriate by the Secretary.

On April 3, 2012, FDA issued a draft guidance for Section 6004. It explained the availability of the Electronics Submission Gateway for submission of the above drug sample information and FDA's temporary compliance policy regarding submissions. FDA provided a walkthrough on how to submit drug sample information through the Gateway, . FDA "strongly encourages" manufacturers and distributors submit drug sample data electronically through the Gateway. Click here for a link providing a download for the XML schema and a user guide with FAQs. 

FDA's New Samples Guidelines

FDA is now issuing new draft guidance, which updates and replaces the 2012 guidance.

Who must submit sample reports to FDA?

FDA defines "drug sample" as "a unit of a prescription drug that is not intended to be sold and is intended to promote the sale of the drug."

The requirements to submit drug sample information applies to manufacturers and "authorized distributors of record" (ADR), which FDA defines as "distributors with whom a manufacturer has established an ongoing relationship to distribute such manufacturer's products." An "ongoing relationship" exists when a manufacturer and a distributor enter into a written agreement whereby the distributor is authorized to distribute the manufacturer's products for a period of time or for a number of shipments. The definition of "distribute" does not include: (1) delivering or offering to deliver a drug by a common carrier in its usual course of business; or (2) providing a drug sample to a patient by a practitioner licensed to provide the drug, by a healthcare professional under the supervision of such a practitioner, or by the pharmacy of a hospital acting at the direction of a licensed practitioner that received a sample in accordance with the FD&C Act and related regulations.

FDA states that "there may be instances when a manufacturer and ADR both have records regarding the same drug sample request or distribution." When, for example, a manufacturer provides a sample to an ADR, which then distributes the sample to a physician, the distribution to the physician should be reported to FDAonly once ― by either the manufacturer or the ADR. Since manufacturers and their ADRs are already required to have written documentation of their relationship, FDA recommends ADR agreements specify who is responsible for reporting the drug sample information.

There may also be instances when requests for samples are transmitted to a manufacturer through an ADR, or when multiple ADRs are used to fulfill a single sample request received by a manufacturer. FDA expects manufacturers to ensure that the submissions for such drug sample requests and distributions are "complete and non-duplicative." FDA believes that manufacturers are best positioned to determine who will do the reporting for their sample requests and distributions. FDA states that they
"will not object if a third party is contracted by the manufacturer to provide the report to FDA, provided the contractor clearly identifies the manufacturer for whom it is reporting. In each such case, the person or firm submitting should identify the manufacturer from whom the report is being made."

What must be submitted to FDA?

The Agency is required under the Paperwork Reduction Act to outline the information they want manufacturers and distributors to report electronically in the Gateway. The list includes:

  • The year the sample was distributed to the provider;
  • The type of business (i.e., either manufacturer or distributor);
  • The business name of the manufacturer or distributor that distributed the sample;
  • The trade name and dosage of the drug sample distributed;
  • Total quantity of the drug requested by the practitioner during the calendar year;
  • Total quantity of the drug distributed to the practitioner during the calendar year;
  • The first name, last name, and middle initial of the practitioner;
  • The practitioner's designation (i.e., M.D., D.O., P.A., or more);
  • Street number, street name, city, state, and ZIP code address of the practitioner;
  • An electronic affirmation that a signed written request for drug samples was received by the manufacturer or ADR from the licensed practitioner and is available to FDA upon request;
  • An electronic affirmation that a signature of the requesting practitioner, or appropriate designee, acknowledging receipt of drug samples has been received by the manufacturer or ADR and is available to FDA upon request;
  • The first name, last name, and middle initial of a practitioner's designee; and
  • Address of the designee.

In summary, manufacturers and ADRs must submit the identity and quantity of drug samples requested and the identity and quantity of drug samples distributed. The information must be aggregated by name, address, professional designation, signature of the practitioner making the request, and signature of the practitioner or the practitioner's designee receiving the distributed drug samples.

FDA states that if someone other than the requesting practitioner receives a sample, that person must be designated by the practitioner as an authorized recipient and sign for the sample on the practitioner's behalf. This situation might arise where samples are delivered to the front desk of the practitioner's office or affiliated pharmacy. These signatures should be collected to comply with the PDMA (which, as stated above, requires a record of the sample), and also now provide the necessary information to compile the reports required by the Affordable Care Act Section 6004.

Identity of drug samples requested or distributed: When reporting drug sample information to FDA, the information provided must "be sufficient for the Agency to identify each unique drug product sample that was requested or distributed." The required elements include:trade name, strength, dosage of the samples, and sample package size (which includes the units/#per unit dosage).

Aggregation of drug sample information: FDA interprets the aggregation requirements to require that the quantity of samples requested and distributed be reported, with respect to each drug product: (1) for each person who makes a drug sample request, and (2) for each person who signs at the time of a drug sample distribution.

Thus, FDA states: "if a practitioner requested 300 samples of drug X and signed for 300 samples of drug X, both quantities would be reported for that practitioner. Alternatively, if a practitioner requested 300 samples of drug Y and designated a pharmacist to sign for 300 samples of drug Y, these quantities would be reported separately for the practitioner and pharmacist. FDA also wants addresses of both the practitioner making the request and the address of the individual who signs for delivery of the requested samples (which may be the same as the practitioner's address).

FDA notes that they "do not believe that the actual, individual signatures must be submitted to comply with the provision in section 6004 that requires 'aggregation' of drug sample information by signature." They note that "[i]t would be impractical for manufacturers or ADRs to submit, and for FDA to receive, such voluminous records." Thus, the Gateway includes checkboxes to indicate whether the signature of the medical practitioner who actually signed a request for samples and the person who signed for the delivered samples (either the requesting practitioner or the practitioner's designee) are on file with the manufacturer or ADR.

For example: Dr. Jones requests 500 samples of drug product X. The manufacturer distributes 250 samples to Dr. Jones at her clinic, and at Dr. Jones' request, the remaining 250 are delivered to Dr. Jones' designee, Mr. Smith, at a different address. The manufacturer determines that it has appropriate signatures on file for the drug sample request and for the samples distributed to Dr. Jones and Mr. Smith. The manufacturer should use the Gateway to report that:

  • Dr. Jones requested 500 samples of drug product X,
  • Dr. Jones received 250 of those samples, and
  • Mr. Smith received the remaining 250 samples.
  • The addresses for both Dr. Jones and Mr. Smith should be provided, and the manufacturer should affirm that it maintains the signature information for Dr. Jones and Mr. Smith by checking the appropriate box in the Gateway submission window.

Period covered by each report

Section 6004 requires reports to be submitted not later than April 1 of each year with respect to the previous year. Thus, "manufacturers and ADRs must report, not later than April 1, 2014, on distributions and requests that occurred between January 1, 2013, and December 31, 2013."

Requests and distributions are to be reported for the year in which they occurred. FDA recognizes that the number of requests and the number of deliveries may not be the same for a given reporting period. For example, if a practitioner requests 100 samples of drug X and the manufacturer fulfills only half of the request before the year ends, a report for that year would show 100 samples requested and 50 distributed. If the manufacturer filled the rest of the request in the following year, the manufacturer would report the distribution of 50 samples to that physician, along with any other distributions made to that physician (or physician's designee) during the calendar year in which the distributions were made.


FDA expects manufacturers and ADRs to comply with section 6004 according to the policies set forth in the guidance, beginning with the submission of data for 2014 due no later than April 1, 2015.

FDA is offering a comment period for its latest samples guidance. Stakeholders should submit either electronic or written comments on the draft guidance by October 9, 2014. Submit either electronic or written comments concerning the proposed collection of information by September 9, 2014.

With respect to the collection of information associated with this draft guidance, FDA invites comments on the following topics: (1) Whether the proposed information collected is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimated burden of the proposed information collected, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information collected; and (4) ways to minimize the burden of information collected on the respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.


Preview | Powered by FeedBlitz


May 2016
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31